Concerning BRAF mutated melanoma, the COMBI-d and COMBI-v (dabrafenib plus trametinib), BRIM-7 (vemurafenib/cobimetinib), and COLUMBUS (encorafenib/binimetinib) trials, testing the different BRAFi/MEKi combinations, showed five-year survival rate of 34-39% 25-27. This evidence concerns the gene BRAF and melanoma.